ArticleOdontology2026
Rg1 activates the AMPK/mTOR-autophagy axis and inhibits the NOD-like receptor 3 inflammasome to alleviate pyroptosis in periodontal ligament fibroblasts.
Article in Odontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Qijia Rougan Formula alleviates liver fibrosis by inhibiting NLRP3-mediated pyroptosis and regulating macrophage polarization.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study explored the mechanism of ginsenoside Rg1 (Rg1) alleviating lipopolysaccharide (LPS)-induced pyroptosis in human periodontal ligament fibroblasts (HPDLFs). HPDLFs were treated with LPS to induce pyroptosis, followed by the Rg1 intervention. Cell viability and lactate dehydrogenase (LDH) release were assessed by CCK-8 and kits. Levels of pyroptosis-related cytokines, NOD-like receptor 3 (NLRP3) mRNA expression, and protein levels of NLRP3 inflammasome-related markers, pyroptosis-related markers, autophagy-related markers, and the AMP-activated protein kinase (AMPK)/mechanistic target of rapamycin (mTOR) pathway were determined by ELISA, RT-qPCR, and western blot. Autophagosome changes were also observed under transmission electron microscopy. HPDLFs were transfected with NLRP3-overexpression plasmids, or co-treated with LPS + Rg1 and the autophagy inhibitor (3-MA), AMPK inhibitor (BML-275), or mTOR activator (MHY1485). LPS increased pyroptosis (decreased cell viability, increased LDH release, increased GSDMD-N-terminal domain protein and IL-1β and IL-18 levels), activated the NLRP3 inflammasome (increased NLRP3, apoptosis-associated speck-like protein containing a CARD, cleaved Caspase-1 protein levels), induced autophagy (increased Beclin1 protein, LC3-II/LC3-I levels, and autophagosome number), impaired autophagic flux, and inhibited p62 degradation. Partial AMPK activation and mTOR inhibition were observed. LPS + Rg1 further activated AMPK/mTOR signaling, mitigated impaired autophagic flux, inhibited the NLRP3 inflammasome, and alleviated HPDLF pyroptosis. Rg1 promoted autophagy by regulating the AMPK/mTOR pathway to inhibit NLRP3 inflammasome activation, thereby inhibiting HPDLF pyroptosis. AMPK inhibition or mTOR activation partially averted Rg1's regulatory effects. Rg1 activates AMPK/mTOR-autophagy axis and inhibits NLRP3 inflammasome, thereby alleviating LPS-induced HPDLF pyroptosis.
Indexed as
Identifiers
41572117What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.